logo

Foamix Pharmaceuticals Ltd. (FOMX)



Trade FOMX now with
  Date
  Headline
2/6/2020 9:08:04 AM Foamix Publishes Phase 3 Studies Evaluating FMX103 For Treatment Of Papulopustular Rosacea
1/17/2020 8:11:11 AM OrbiMed To Vote In Favor Of Proposed Merger With Menlo Therapeutics At Extraordinary General Meeting Of Shareholders
1/14/2020 8:41:41 AM Foamix Announces AMZEEQ Achievement Of Preferred Status On Express Scripts National Preferred Formulary
1/9/2020 8:06:03 AM Foamix : AMZEEQ Topical Foam Available In Pharmacies Nationwide On Jan 13th For Treatment Of Moderate To Severe Acne
11/18/2019 9:10:28 AM Foamix Completes Phase 2 Clinical Trial Enrollment Of FCD105 For Treatment Of Moderate-to-severe Acne Vulgaris
11/11/2019 6:08:44 AM Foamix Reports Net Loss Of $23.2 Mln, No Revenues In Q3
11/11/2019 6:04:23 AM Foamix Pharmaceuticals And Menlo Therapeutics To Merge
11/4/2019 8:18:46 AM Foamix Announces Publication Of AMZEEQ Topical Foam Long Term Safety Data For Treatment Up To 1 Year
10/21/2019 8:15:42 AM Foamix Enters Deal To Resolve Pending Patent Litigation Involving Finacea Foam
10/17/2019 11:23:43 AM Foamix : FDA Accepts NDA For FMX103 Minocycline Foam For Treatment Of Moderate-to-Severe Papulopustular Rosacea
10/17/2019 8:29:36 AM Foamix Announces FDA Acceptance Of NDA For FMX103 Minocycline Foam For Moderate-to-Severe Papulopustular Rosacea
8/5/2019 8:04:19 AM Foamix Submits NDA To FDA For FMX103 For Moderate-to-Severe Papulopustular Rosacea
4/2/2019 8:13:33 AM Foamix Announces Settlement Of Litigation With Perrigo Relating To Finacea Foam
3/7/2019 8:20:22 AM Foamix Reports FDA Acceptance Of NDA For FMX101 Minocycline Foam
12/21/2018 7:02:50 AM Foamix Submits NDA To U.S. FDA Seeking Approval Of FMX101 In Treatment Of Moderate-to-Severe Acne
  
 
>